Janus kinase (JAK) and pharmacokinetics Archives

Abstract Number: 1480 • ACR/ARHP Annual Meeting 2014
Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach
Florence Namour¹, Chantal Tasset², Béatrice Vayssièrre³, Gerben van 't Klooster⁴, Paul Diderichsen⁵ and Eugène Cox⁶, ¹102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, ²Generaal de Wittelaan L11 A3, Galapagos NV, Mechelen, Belgium, ³Galapagos SASU, Romainville, France, ⁴Galapagos NV, Mechelen, Belgium, ⁵Quantitative Solution, Breda, Netherlands, ⁶Quantitative Solutions, Breda, Netherlands
Background/Purpose: GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Selective inhibition of JAK1 may combine favorable safety and clinical efficacy profiles with rapid…

Abstracts tagged "Janus kinase (JAK) and pharmacokinetics"